Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATGC-100 vs Botox for Moderate to Severe Glabellar Lines
NCT04830345Phase 3Completed
- Sponsor
- EuBiologics
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of ATGC-100 in glabellar lines, sponsored by EuBiologics. Started Jun 2020; status: completed.
02
Drugs
ATGC-100
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT04830345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830345.